Interferon-alpha for chronic hepatitis C: reducing the uncertainties

Editorial

R S Koff. Ann Intern Med. 1997.

. 1997 Nov 15;127(10):918-20.

doi: 10.7326/0003-4819-127-10-199711150-00011.

No abstract available

Comment on

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.
Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Bennett WG, et al. Ann Intern Med. 1997 Nov 15;127(10):855-65. doi: 10.7326/0003-4819-127-10-199711150-00001. Ann Intern Med. 1997. PMID: 9382363
Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C.
Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, Gross JB Jr. Kim WR, et al. Ann Intern Med. 1997 Nov 15;127(10):866-74. doi: 10.7326/0003-4819-127-10-199711150-00002. Ann Intern Med. 1997. PMID: 9382364
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S. Marcellin P, et al. Ann Intern Med. 1997 Nov 15;127(10):875-81. doi: 10.7326/0003-4819-127-10-199711150-00003. Ann Intern Med. 1997. PMID: 9382365